Stay updated with breaking news from Danilo Lembo. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Interim data presented at the European Academy of Neurology 2022 shows that 54.7% of patients in the study had their monthly-migraine-days reduced by 50% or more over the six-month period from the start of treatment.
Teva Announces Promising Interim Results From Its Study PEARL, About the Impact of AJOVY® (fremanezumab) - read this article along with other careers information, tips and advice on BioSpace
Interim data presented at the European Academy of Neurology 2022 shows that 54.7% of patients in the study had their monthly-migraine-days reduced by 50% or more over the six-month period from the start
Press release content from Business Wire. The AP news staff was not involved in its creation.
Teva Pharmaceuticals Europe BV has confirmed that the SmPC for COPAXONE® (Glatiramer Acetate (GA) injection) 20mg/mL and 40mg/mL, indicated for the treatment of relapsing forms of multiple sclerosis (RMS) in Europe, has been updated.